Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News XOMA Royalty completes LAVA Therapeutics acquisition in push to strengthen bispecific antibody pipeline Find out how XOMA Royalty’s acquisition of LAVA Therapeutics strengthens its oncology royalty portfolio and expands its partnered bispecific antibody programs. bySoujanya RaviNovember 21, 2025